Could a single infusion of modified immune cells tame autoimmune attacks?

NCT ID NCT06680037

Recruiting now Disease control Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destroy faulty B-cells. The main goal is to find a safe dose and see if it can control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MEDIATED AUTOIMMUNE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease chronic inflammatory demyelinating polyradiculoneuropathy multiple sclerosis myasthenia gravis neuromyelitis optica primary progressive multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MEDIATED AUTOIMMUNE DISORDERS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

TG Therapeutics Investigational Trial Site
RECRUITING

La Jolla, California, 92093, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Ann Arbor, Michigan, 48019, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Omaha, Nebraska, 68198, United States
TG Therapeutics Investigational Trial Site
RECRUITING

New York, New York, 10025, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Rochester, New York, 14642, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Cleveland, Ohio, 44195, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Columbus, Ohio, 43210, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.